“Regeneron mentioned that on their ESMO update yesterday, they're Head of Translational Medicine, Oncology that they're running a program with you in GBM. Could you just give us an update on that 5401?
JK
Regeneron has been a fantastic partner in this trial, in this program. GBM, as you know, is the deadliest cancer out there and this has always been a high-risk, high-benefit, aiming for the fences, so to speak. And all along the way, our treatment of newly diagnosed GBM patients with INO-5401 along with 9012 which is our IL-12 plasmid -- deliver IL-12, along with Regeneron's PD-1 inhibitor, we've shown very encouraging better than standard of care survival at PFS6, overall survival at 12 months, 18 months. And certainly, as we stated, we plan to present at a fourth quarter cancer conference, our results of OS24 but also median OS. And I don't want to take the punchline but we have been achieving better than standard of care in each of those characteristics and milestones.
So we couldn't be any happier in the progress from this trial.
We also plan to bring out what our next steps might be around that time. So as I said, Regeneron has been a wonderful partner and we look forward to executing with them this trial and potentially additional ones to come.”
Jeffries on 11/18, Piper on 11/22 coincide with SNO conference 11/18-11/21 where Ino will present GBM 5401 OS24, correlation of protection, tissue data.
This is a great opportunity for JK to shine a spotlight on 5401, it’s roadmap, and share further collaboration with REGN.
